NCT05481931View on ClinicalTrials.gov

Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines

Active, not recruitingOBSERVATIONAL
Enrollment

756

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Glabellar Frown Lines
Interventions
DRUG

prabotulinumtoxinA

Botulinum toxin Type A powder for solution for injection

Trial Locations (1)

Unknown

Cologne Dermatology, Cologne

Sponsors

Lead Sponsor

Evolus, Inc.

Collaborators (1)

Avania
All Listed Sponsors
collaborator

Avania

INDUSTRY

lead

Evolus, Inc.

INDUSTRY